SCHEMBL20244436

SCHEMBL20244436

COc1cc(C)cc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 0.50
▸ MAOB P27338 2/20 0.50
▸ ALDH1A1 P00352 5/20 0.48
▸ LMNA P02545 4/20 0.48
▸ MAPT P10636 4/20 0.48
▸ KRAS P01116 2/20 0.47
▸ NTSR1 P30989 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ COMT P21964 1/20 0.45
▸ TXNRD1 Q16881 1/20 0.45
▸ TXNRD3 Q86VQ6 1/20 0.45
▸ TXNRD2 Q9NNW7 1/20 0.45
▸ GABRA3 P34903 1/20 0.44
▸ GABRA2 P47869 1/20 0.44
▸ GABRB2 P47870 1/20 0.44
▸ APP P05067 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15807358 0.89 MAOA (0.50) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL20244282 0.86 MAOB (0.67) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL15807359 0.84 MAOB (0.71) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL15807292 0.82 MAPT (0.53) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL14318104 0.81 MAOA (0.54) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL15795973 0.81 MAOA (0.54) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL15807325 0.81 MAPT (0.70) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL15807304 0.80 MAPT (0.66) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL29083859 0.77 TYR (0.65) MAOAMAOBALDH1A1LMNAMAPT
SCHEMBL27631290 0.77 TYR (0.65) MAOAMAOBALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3333153-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) 2018-06-13 — — EP disclosed
Send feedback